




Contents lists available at ScienceDirect

Understanding Modern Vaccines: Perspectives in Vaccinology



Index

Note: Page numbers followed by *f* and *t* denote figures and tables, respectively.

- Adaptive immune receptors, diversity of, 36
- Adaptive immune system, 28*f*, 30, 36–51 *see also* Immune system
- antibodies, effector functions of, 40–41, 42*f*
- antigen-presenting cells, role of, 36–38, 47–48
- B cells, 40–41
- CD4⁺ T cells, 38–39
- CD8⁺ T cells, 39–40
- cytokines, role of, 43
- distinguished from innate immune system, 46
- immunological memory, 44–46
- regulatory T cells, 43
- T-cell activation, 38
- Addiction, prophylactic and therapeutic vaccines for, 187–189
- Adjuvant combinations, in licensed vaccines, 102–106
- Adjuvants, 13–14, 153–160
- achievements of, 153–155
- antigen identification and purification, new approaches to, 155–159
- antigen selection and stability, new approaches to, 155
- role in future vaccines, 155, 154*f*, 156*t*–157*t*
- in vaccines, 89–111, 90*f*
- aluminium salts, 91, 93*t*, 95–97, 97*t*
- AS01, 107–110
- AS03, 94*t*, 105–106, 106*f*
- AS04, 93*t*, 103–105, 104*f*
- AS15, 110
- benefits of, 92
- defined, 89–91
- emulsions, 92, 93*t*, 99–101, 100*f*
- first use of, 91
- on immune mechanisms, impact of, 94–95, 96*f*
- innovative adjuvants, need for, 92
- microbial DNA immunostimulatory sequences, 107, 108*f*
- Montanide™ ISA51, 93*t*, 107
- natural immune-defence triggers, mimicking, 95
- persistence of, 95
- role of, 92, 95, 111
- safety profile of, 110–111
- selection of, 91
- synthetic MPL (RC-529), 93*t*
- thermo-reversible oil-in-water emulsion, 94*t*
- virosomes, 93*t*
- Administration of vaccines, 167–171
- Advanced market commitments (AMCs), 119
- Adverse events and vaccination, temporal associations between, 145
- Adverse events of special interest (AESI), 137*t*, 139
- Aerosol delivery, 172
- AIDSVAX™, 182

- Alliance for Case Studies for Global Health, 186
- Aluminium hydroxide, 95, 97*t*
- Aluminium hydroxyphosphate sulphate, 97*t*
- Aluminium phosphate, 95, 97*t*
- Aluminium salts, 91, 92, 93*t*, 95–97, 97*t*
limitation of, 97
- Anopheles* spp mosquito, 178*f*
- Antibiotics, 180
- Antibodies, 37*f*, 52–54, 64, 82*f*, 83, 91, 92, 134, 142, 159, 164, 174, 184
anti-diphtheria toxin, 26
anti-HAV, 142, 144
discovery of, 12, 26
effector functions of, 39–40, 42*f*, 53
- Anti-diphtheria toxin antibodies, 26
- Antigenic drift, 179–180
- Antigen-presenting cells (APCs), 28, 30, 34, 57, 94, 98, 101, 155
role of, 36–38, 46–47
- Antigens
bacterial vector vaccines, 162–165, 165*f*, 166*t*
delivery, new approaches of, 160–167
dendritic cell vaccines, 167
DNA vaccines, 165–167
identification and purification, new approaches to, 155–159
pathogen peptide libraries, 159
poly-epitope vaccines and MHC restriction, 158
reverse vaccinology, 158
presentation, issues affecting, 160–161
research and discovery, key areas of, 157*t*
selection and stability, new approaches to, 155
stability, 159–160
vaccine see Vaccine antigens
- viral vector vaccines, 161, 162*f*, 163*t*–164*t*
- Antigen-specific cancer immunotherapeutics (ASCI), AS15 for, 110
- Antitoxin, as immune serum, 13, 62
- AS01, 107–110, 156*t*, 179
- AS03, 94*t*, 105, 155
structure of, 106*f*
- AS04, 92*t*–93*t*, 103–105, 104*f*, 155, 157*t*, 176
-adjuvanted HPV-16 vaccine, 125–126
-adjuvanted HPV-18 vaccine, 125–126
- AS15, 157*t*
for antigen-specific cancer immunotherapeutics, 110
- Association of University Technology Managers (AUTM), 186
- Attenuation
of live vaccines, loss of, 69
of pathogens, 10, 65, 128
of vaccines, 10, 22
- Autism, MMR vaccination and, 146–147
- Autoimmune diseases, 125, 149
definition of, 142
- Autoimmunity and vaccines, 144–145
- Bacille Calmette Guérin (BCG)
vaccine, 14, 69, 170, 173
- Bacterial pathogen, 55–56
- Bacterial vector vaccines, 162–164, 165*f*
advantages and disadvantages of, 169*t*
in clinical development, 163*t*–164*t*
- Balmis, Francisco Xavier de, 8
- B cell receptors (BCR), 40–42
- B cells, 40–42
- Behring, Emil von, 12
- Bill & Melinda Gates Foundation, The, 163*t*–164*t*, 183
- Biologics License Application (BLA), 131, 136
- Bordetella pertussis* infection, 193
- Calmette, Albert, 14
- Canarypox vector vaccine (ALVAC™), 182
- Cancer
cervical, 19, 84
infectious diseases associated with, 188*t*–189*t*
immunotherapeutics, antigen-specific, 110
non-small-cell lung, 107
prophylactic and therapeutic vaccines for, 187–189, 188*t*–189*t*
prostate, 167
- Cathelicidins, 31
- CD4⁺ T cells, 38–39
help, induction of, 53
- CD8⁺ T cells, 39–40
- Cell culture era, 14–15
- Center for Biologics Evaluation and Research (CBER), 131, 132
- Centers for Medicaid and Medicare Services (CMS), 139
- Chamberland–Pasteur filter, 15
- Charles IV of Spain, 8
- Chemokines, 32, 34, 95, 105
- Circulating recombinant forms (CRFs), 182, 183*f*
- Clinical assessment or development, of vaccines
overview of, 123–124
Phase I trial, 123
Phase II trial, 123
Phase III trial, 123
Phase IV trial, 123
safety evaluation, 124, 124*f*
- Cocaine candidate vaccine, 187
- Cold chain, 119, 152, 159

- Committee for Medicinal Products for Human Use (CHMP), 129, 134
- Complement system, 34–36
- Conditional approval, for vaccines, 135
- Council for International Organizations of Medical Sciences, 136
- Cowpox vaccination, for smallpox, 6
see also Vaccination
- CpG 7909, 107, 108f
- Current good manufacturing practices (cGMP), 122
- Cutter incident, 15
- Cytokines, 32, 34, 37f, 38–40, 42–43, 45, 47, 48, 82, 93, 94f, 101, 141
- Cytomegalovirus (CMV), 56, 71, 173–175
reactivation of, 176
- Cytotoxic T cells, 49, 50
- Damage-associated molecular patterns (DAMPs), 97
- Defensins, 31
- Dendritic cell (DC) vaccines, 167, 169t
advantages and disadvantages of, 169t–170t
- Dendritic cells (DCs), 34, 38, 94
- Department of Defense (DOD), 139–140
- Depot effect, 91
- Development of vaccines, 63f, 116
case study, 125–126
challenges to, 143–144, 146–147
autoimmunity and vaccines, 144–145
case study, 54–55, 142–147
protective effects, measurement of, 142–143
temporal associations between adverse events and vaccination, 145–147
clinical evaluation, 123–125
using immune correlates of protection, 143
- ingredients, safety concerns of, 147–148
modern elements of, 153f
pathogens, identification and selection, 120
post-licensure surveillance, 136–137
case study, 139–140
preclinical evaluation, 120–121
principles of, 117–120
production of vaccines, 126–136
safety assessment, improvement in, 148
- Diphtheria, 22
bacillus, 13
burden of, 14
immunotherapy of, 14, 26
- Disease burden, assessment of, 117–120
medical need and economic resources, 118
recent science and technology discoveries, 119–120
vaccine programmes, funding, 118–119
- DNA expression libraries, 159
- DNA recombinant vaccines, 18–19, 165–166
advantages and disadvantages of, 169t–170t
in clinical development, 168t
- Effector(s)
adaptive immune, 37f, 39–41
cells, selection and targeting of, 53–54
functions of antibodies, 40–41, 42f
innate immune, 34–36, 35f
- Ehrlich, Paul, 13, 26, 64
- Elderly, vaccines for, 193
- Embryonated eggs, 14
- Emergency procedure, pandemic
influenza vaccines authorisation using, 134f, 135–136
- Emulsions in vaccines, 98–102f, 99f
oil-in-water, 79, 93f, 100–102, 100f, 101f
water-in-oil, 92, 100, 100f, 107
- Enders, John, 15
- Epithelial cells, 31
- Epitope-based vaccines, 158
- Epitope mapping, 158
- Europe, variazione in, 4
- European Commission (EC), 129
- European Medicines Agency (EMA), 129, 139
- European Union (EU), vaccine
licensing procedures, 129, 130f
centralized procedure, 129
mutual recognition and decentralised procedures, 129–132
- Evolution of vaccines, 1–24, 12f
- Exotoxins, 12 see also Toxins
- Fibroblasts, 31
- Flagellin, 156t–157t
- Follicular helper cells, 39
- Food and Drug Administration (FDA), 122, 136
Investigational New Drug (IND)
application, 122, 131
- Formaldehyde inactivation, in vaccines, 11, 15
- Future vaccines, 149
adjuvants, 153–160
antigen delivery, new approaches of, 160–167
complex and challenging targets, new vaccines for, 172–187
non-infectious conditions, vaccines for, 187–191
specific populations, vaccines for, 191–195
vaccine administration, new approaches to, 167–171

- Gene–environment interaction, 187
- Genital HSV-2 infection, 175–176
- Genocea
 T-cell antigen discovery technology, 159, 160*t*
- German measles *see* Rubella
- Germ theory of disease, 8
- Glenny, Alexander, 13, 91, 97
- Global Advisory Committee on Vaccine Safety (GACVS), 139
- Global Alliance for Vaccines and Immunisation (GAVI), 118–119
- Global Solutions for Infectious Diseases, 182
- Glycerine, 6
- Goodpasture, Ernest, 14
- Group A streptococcus, 183–184
- Guérin, Albert, 14
- H1N1 pandemic influenza, 135, 139, 192
- Haemophilus influenzae* type b (Hib) vaccine, 20, 81, 86*t*, 118–119
- Heads of Medicines Agencies (HMA), 131
- Helper T cells, 38–39
- Hepatitis A vaccines, 143–144
 active immunization, 144
 passive immunization, 144
- Hepatitis B virus (HBV) vaccine, 18–19, 69, 76, 125
 antigen, recombinant proteins for, 83–84
- Herpes simplex virus (HSV), 71, 175–177
 vaccines, possible effects and consequences of, 176*t*
- Host–pathogen interactions, 55
 diseases with complex, 142
- HPV-16, 19
- HPV-18, 19
- HPV L1 coat protein, 19
- HSV-2 glycoprotein D (gD2) candidate vaccine, 176
- Human Hookworm Vaccine Initiative (HHVI), 186
- Human immunodeficiency virus (HIV), 92, 143, 152
 vaccines, 55
 candidates, targets of, 184
 development of, 183
- Human immunodeficiency virus 1 (HIV-1), 182
 subtypes, 183*f*
- Human leukocyte antigens (HLA), 38
- Human Microbiome Project, The, 187
- Human papilloma virus (HPV), 19
 L1 synthesis, in yeast expression system, 77*f*
 recombinant antigens for vaccines against, 84
 vaccines, 76
 AS04-adjuvanted, 105
- IC31™, 156*t*
- Immune correlates of protection, 54–55
 vaccine development by, 142
- Immune system, 28–46
 adaptive, 28*f*, 30, 36–51
 innate, 28*f*, 30–36, 46–51
 interaction of vaccines with, 58–59
 organs and tissues of, 29*f*
- Immunisation, 13, 118–119, 136, 194
 active, 144
 neonatal, 193
 passive, 144
 polio, 17
 RRR-TV, 140
- Immunity, 3
 adaptive, 30
 innate, 30
- Immunocompromised individuals, vaccines for, 194–195
- Immuno-evasion, 71
- Immunological impediments to vaccination, 57
- Immunological memory, 44–46
 responses, kinetics of, 45*f*
- Immunological requirements, of vaccines
 antigen, identification and selection of, 52
 CD4⁺ T-cell help, induction of, 53
 effector cells, selection and targeting of, 53–54
 innate immune responses, induction of, 52–53
- Immunological senescence, 79
- Immunology of vaccines, 25–59
 history of, 26–28
- Immunostimulatory sequences (ISS), 107, 156*t*
- Immunotherapy, 12–14
- Inactivated polio vaccine (IPV), 15
- Independent Data Monitoring Committees (IDMCs), 124
- Influenza vaccines, 18, 73, 182*t*
 antigens for, 78–79
 pandemic, 79
 seasonal, 78–79
 types of, 77*f*
- Innate immune system, 28*f*, 30–36, 46–51, 144 *see also* Immune system
 cells of, 30–31
 complement system, 34–36
 distinguished from adaptive immune system, 46
 innate response, effectors of, 34–36, 35*f*
 pathogens, detection of, 31–34
- Inoculation, 4, 7*f*
- Interferon-gamma (IFN γ), 39
- Interleukin-4 (IL-4), 39
- Interleukin-5 (IL-5), 39
- Interleukin-13 (IL-13), 39

- International AIDS Vaccine Initiative (IAVI), 186
- Intramuscular vaccination, 50–51, 51f
- ISCOM™ (immune-stimulating complex consisting of cholesterol and phospholipids), 109
- ISCOMATRIX™, 156t
- Jenner, Edward, 5, 7f, 62, 152
- Killed/inactivated pathogen vaccines, 10, 11, 17, 60, 64, 68–69, 89–90
- characteristics of, 72t
- influenza, 17
- Pneumococcus*, 19
- polio, 15
- Kitasato, Shibasaburo, 13
- Koch, Robert, 6, 8, 26, 62
- postulates, 8
- Large-scale vaccine manufacturing, 127
- Latency, 71
- Lederberg, Joshua, 186
- Licensing procedures, for vaccines (in EU), 129–132, 130f
- centralised procedures, 129
- emergency procedure, 134f, 135–136, 135t
- mock-up procedures, 130–131, 130f, 132t
- mutual recognition and decentralised procedures, 129–132
- Lipkin, Ian, 186
- Lipopolysaccharide (LPS), 33
- chemical structure of, 103, 104f
- Liposomes, 98–99
- structure of, 98f
- Live, attenuated pathogen vaccines, 10, 14, 15, 21, 65, 68, 77, 170, 184, 192
- characteristics of, 72
- Live vector vaccine, 184
- LT, 156t
- LuJo virus, 186
- Lyzozymes, 31
- Macrophages, 94
- Madhava Nidana, 4
- Major histocompatibility complex (MHC), 38–39
- restriction, 158
- Measles-mumps-rubella (MMR) vaccine, 17, 119, 144–145
- Measles vaccine, aerosolised, 170
- Meningococcal polysaccharide vaccines, 19–20
- Metchnikoff, Élie, 13, 26
- MF59™, 93t, 101–102, 155, 156t–157t, 175, 193 *see also* Oil-in-water emulsions
- structure of, 101f
- Microbes, 8
- Microbial DNA immunostimulatory sequences, 107
- structure of, 108f
- Microbiome, 186
- Microneedles, 171f
- Mock-up procedure, pandemic influenza vaccines authorisation using, 132–134, 133f, 134t
- Monocytes, 94
- Monophosphoryl lipid A (MPL), 103, 104f, 157t
- Montague, Mary Wortley, 5f
- Montanide™ ISA51, 93t, 107, 157t
- see also* Water-in-oil emulsions
- Montanidec ISA720, 156t
- Multifactorial vaccine development process, 121
- Multiple puncture method, 7–8, 8f
- Mumps, 146–147
- Mycobacterium bovis* bacillus, 14, 173
- Mycobacterium leprae*, 69
- Mycobacterium tuberculosis* (*M. tuberculosis*), 55, 71, 173, 174t
- Naïve T lymphocytes, 38
- NanoBio Corp., 155
- Nanoemulsions, 155
- NanoStat™, 156t
- National Regulatory Authorities (NRA), 132
- Natural immunity to infection, 13
- Natural killer (NK) cells, 71
- Neisseria gonorrhoeae*, 53
- Neisseria meningitidis*, 81
- Neonatal infants, vaccines for, 193
- Neonatal tetanus, 13 *see also* Tetanus
- New onset of chronic disorders (NOCDs), 125
- New vaccines, for complex and challenging targets, 172–187
- neglected tropical and non-tropical diseases, 185–186
- pathogens
- with complex life cycle, 177–179
- exhibiting antigenic variability, 179–184
- novel and emerging, 186
- persistent infections and malignancy, 172–177
- undesirable immune responses, 185
- Nicotine vaccine, 189
- Nigera, polio outbreak in, 22
- Non-infectious conditions, vaccines for, 185t–186t, 187–191, 188t–189t
- addiction, prophylactic and therapeutic vaccines for, 187–189
- cancer, prophylactic and therapeutic vaccines for, 189–191
- North America, variolation in, 4
- Novartis Vaccines Institute for Global Health, 186

- Oil-in-water emulsions, 79, 93*t*, 100, 100*f* see also Emulsions in vaccines
 MF59™, 93*t*, 99–100, 99*f*, 101–102, 101*f*
 thermo-reversible, 94*t*, 102
- Oral polio vaccine (OPV), 15
- Pan American Health Organization
 Revolving Fund for Vaccine Procurement, 119
- Pandemic influenza vaccines, 77
 see also Influenza vaccines
 EU authorization of, 132–136
 using emergency procedure, 134*f*, 135–136, 135*t*
 using mock-up procedure, 133*f*, 134–135, 135*t*
 post-authorisation studies of, 133*t*, 136–142, 137*t*
- Parasites, 39, 56–57, 177, 185
- Particulate antigens, 83–85
- Pasteur, Louis, 8, 26, 62
- Pathogen-associated molecular patterns (PAMP), 31
 effectors, 33*f*
 recognition of, 94
 sensors, 33*f*
- Pathogen peptide libraries, 159–160
- Pathogens
 attenuation of, 8–11
 causing persistent infections, 174*t*
 complexity, 70–71
 with complex life cycle, 177–179
 detection of, 31–34
 exhibiting antigenic variability, 179–184
 identification and selection, 120
 inactivated, 10
 novel and emerging, 186
 recognition of, 94–95
 split-pathogen, 73
 whole organism vaccines for, 17–18
- Pattern recognition receptors (PRRs), 31, 94
 intracellular, 33*f*
- Peptide approaches to vaccine antigens, 66, 67*f*
- Periodic safety update report (PSUR), 137
- Persistent infections
 pathogens causing, 174*t*
 vaccines addressing, 172–177
- Pertussis, 17, 22, 143, 192
- Pertussis vaccine, 17, 71, 73
 acellular, 193
- Phagocytes, 13, 26
- Pharmacovigilance, vaccine, 136–142
 background incidence of events, understanding, 140–142
 case study, 139–142
 considerations, 138*f*
 definition of, 136
 regulation processes for safety and immunogenicity, 139–140
- Phipps, James, 152
- Plasmodium falciparum*, 177–178
 life cycle of, 178*f*
- Plasmodium* parasite, 71
- Pneumococcal vaccines, 19–20
- Polio, 15–17
 eradication of, 2–3
 outbreak in Nigera, 22
 outbreak in Tajikistan, 22
 vaccine, 21
- Poly-epitope vaccines, 158
- Polysaccharide conjugate vaccines, 80–81, 82*f*
- Post-licensure surveillance, pandemic influenza vaccines, 136–142, 137*t*
- Pregnant women, vaccines for, 192
- 'Prime-boost' approach, 184
- QS21, 107–110
 chemical structure of, 109*f*
- Quality-adjusted life years (QALYs), 117
- Quality control (QC), of vaccines, 128–129
- Ramon, Gaston, 12, 13, 91
- Reassortant viruses, 21–22
- Recombinant/DNA technology
 approaches to vaccine antigens, 64–66, 66*f*
 generation of short peptide antigens by, 76, 77*f*
- Recombinant modified vaccinia Ankara (rMVA), 161, 163*t*, 175*t*, 191*t*
- Reference Member State (RMS), 131
- Regulatory T cells (T_{reg} cells), 43
- Resiquimod, 156*t*
- Respiratory syncytial virus (RSV)
 vaccines, 55, 67–68, 70, 182, 185
- Reverse vaccinology, 74, 74*f*, 158
- Rhesus rotavirus tetravalent vaccine (RRV-TV) (Rotashield™), 139–142, 145
- Robbins, Frederick, 15
- Rotarix™ (RV1), 141
- RotaTeq™ (RV5), 141
- Rotavirus infection, 140–142
 vaccination
 previous attempts to, 140–141
 recent attempts, 141–142
- Rotavirus vaccine, 22
- Roux, Émile, 8, 12
- Royal Jennerian Society, 6
- Royal Philanthropic Expedition, 8
- RTS,S recombinant malaria candidate vaccine antigen, structure of, 179
- Rubella, 146

- Sabin, Albert, 15
- Safety assessment or monitoring, of vaccines, 124*f*
- clinical safety evaluation, 124–125
 - continuous improvement in, 148
 - vaccine ingredients, 147–148
- Salmonella enterica*, 56
- Seasonal influenza vaccines, 78–79
- see also Influenza vaccines
- Serious adverse events (SAEs), 125
- Serious unexpected suspected adverse events (SUSARs), 137
- Seroprotection rates, 142
- Serotype replacement, 180
- Short peptide antigens
- direct synthesis of, 76
 - generation of, by recombinant DNA technology, 76, 77*f*
- Sipuleucel-T, 167
- Smallpox, 4*f*
- cowpox vaccination for, 6–7
 - variolation for, 4, 5*f*
 - inoculation procedure, 4, 7*f*
- Speckled monster, 4
- Split-pathogen approaches to vaccine antigens, 17–18, 73, 128
- see also Pathogens
 - characteristics of, 75
- Streptococcus pneumoniae*, 81
- Subunit antigens, 17–18, 21–22, 52, 61, 73, 128
- characteristics of, 75
 - defined, 73–75
 - limitations of, 75
- Synthetic MPL (RC-529), 93*t*
- Syphilis, 4
- Tajikistan, polio outbreak in, 22
- T-cells
- activation of, 38
 - antigen discovery technology, 159, 160*f*
- Tetanus
- neonatal, 13
 - vaccination, 13
- Theiler, Max, 14
- Thermo-reversible oil-in-water emulsion, 94*t*, 102 see also Oil-in-water emulsions
- Thiomersal, 147–148
- Toll-like receptors (TLRs), 31, 94
- mammalian, 32*t*
- TORCH pathogens, 192
- Toxins, 11–13
- anatoxin, 13
 - exotoxins, 12
- Toxoids, 12, 62, 81
- Transdermal microneedle patches, 170
- Tuberculosis (TB), 4, 172–173
- Tumour-associated antigens (TAA), 189
- Typhoid fever vaccine, 11
- 'Typhoid Mary', 11*f*
- UK National Health Service (NHS), 146
- United Nations Children's Fund (UNICEF), 132
- United States
- impact of vaccines in, 21*t*
- Vaccination
- boosting in, 45*f*
 - cowpox, 4–6
 - evolution of, 3
 - immunological impediments to, 57
 - intramuscular, 51*f*
 - priming in, 45*f*
 - programme (first), 8
 - programmes, adherence to, 22
 - tetanus, 13
- Vaccine Adverse Event Reporting System (VAERS), 139
- Vaccine antigens, 60–87
- defined, 64
 - discovery of, 64
 - future of, 85
 - HBV vaccine antigen, recombinant proteins for, 83–84
 - identifying and producing, 64–68, 63*f*
 - for influenza vaccines, 78–79
 - on nature, building and improving, 80
 - particulate antigens, 83
 - peptide approaches to, 66, 67*f*
 - polysaccharide conjugate vaccines, 80–81, 82*f*
 - recombinant/DNA approaches to, 65–66, 66*f*
 - short peptide antigens
 - direct synthesis of, 76
 - generation of, by recombinant DNA technology, 76, 77*f* - whole-pathogen-based see Whole-pathogen-based vaccines
- Vaccine Safety Data (VSD) link system, 139
- Vaccines and Related Biological Products Advisory Committee (VRBPAC), 132
- Vaccinology, immunological milestones of, 27*t*
- Varicella zoster virus, 71
- Variolation, 6*f*
- in Europe, 4
 - mortality associated with, 4
 - in North America, 6
- Vascular endothelial cells, 31
- Veterans' Health Administration (VHA), 139
- Viral vector vaccines, 161, 162*f*, 163*t*–164*t*
- advantages and disadvantages of, 169*t*–170*t*
- Virosomes, 93*t*, 98–99
- structure of, 98*f*

- Viruses, 56
 as infectious agents, 15
- Vitamin E, 105
- Water-in-oil emulsions, 92, 99, 98*f*
 see *also* Emulsions in vaccines
 Montanide™ ISA51, 93*t*, 107
- Wellcome Trust Hilleman Laboratories,
 186
- Weller, Thomas, 15
- Whole-pathogen-based vaccines,
 17–18, 65*f*
 killed/inactivated pathogen
 vaccines, 68–72, 72*t*
- limitations of
 attenuation of live vaccines, loss
 of, 69
 high reactogenicity, 69
 latency and immunoevasion, 71
 pathogen complexity, 70–71
 reduced immunogenicity,
 71–72
 reversion, risk of, 70
 unwanted immune response,
 70
- live, attenuated pathogen vaccines,
 69, 70, 72*t*
- split-pathogen, 17–18, 73, 128
- subunit antigens, 18, 22, 52, 73, 90,
 128, 158, 184
- World Health Organization (WHO), 2,
 132, 185
 CHOICE (CHOosing Interventions
 that are Cost-Effective) project,
 118
 polio position paper, 15–17
- Yersin, Alexandre, 12
- Zoster vaccine, 172